Education
About Us
Working with TipRanks
Follow Us
Rhythm Biosciences Ltd. (AU:RHY)
ASX:RHY
RHY Stock Chart & Stats
AU$0.14
<AU$0.01(1.16%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(1.16%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.28
Previous CloseN/A
Volume786.78K
Average Volume (3M)462.98K
Market Cap
AU$72.52M
Enterprise ValueAU$65.68M
Total Cash (Recent Filing)AU$1.73M
Total Debt (Recent Filing)AU$262.44K
Price to Earnings (P/E)―
Beta0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding337,305,330
10 Day Avg. Volume510,821
30 Day Avg. Volume462,976
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)22.03
Price to Sales (P/S)4.56
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Core Product (Colostat)Rhythm's concentrated strategy around Colostat targets a durable, structural market need: population colorectal screening. A validated, blood-based screening test can achieve steady clinical adoption and payer coverage, creating a defendable niche and scalable revenue base as trials and approvals progress.
High Gross Profit MarginReported high gross margins point to attractive per-test economics that can sustain pricing and support profitability as volume grows. If fixed R&D and SG&A are leveraged over expanding volumes, operating leverage can materially improve margins and long-term earnings power.
Improving Free Cash Flow TrendsAn improving free cash flow trend, with FCF covering net income on a ratio slightly above one, indicates early progress toward cash generation. While absolute cash flows remain weak, the trend reduces financing pressure and enhances flexibility to fund staged commercial rollout and clinical programs.
Bears Say
Sharp Revenue DeclineA 42.87% year decline in revenue is a material structural concern: it undermines the ability to scale fixed-cost-intensive diagnostics work, delays breakeven, and raises questions about product adoption or commercialization execution. Persistent declines impede margin recovery and growth plans.
Elevated Leverage And Poor ROEDebt-to-equity of 1.68 combined with negative ROE signals elevated leverage and poor capital efficiency. High leverage increases interest and refinancing risk, constrains investment in trials and commercialization, and limits strategic flexibility until operating performance and returns improve.
Negative Operating Cash FlowOngoing negative operating cash flow means core operations consume cash and the company remains reliant on external funding or reserves. Even with improving FCF trends, persistent negative OCF over months threatens runway and could force cutbacks or dilution if operational cash generation is not restored.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$72.52M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Currently, no data Available
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 337,305,330 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHY Sentiment 66%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$34.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-501.54%
Trailing 12-Months
Asset Growth
86.46%
Trailing 12-Months
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―